Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery

Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.

Inclusion Criteria: * Aged 18 to 65 years; * Providing written informed consent; * Patients scheduled to undergo elective minimally invasive endoscopic surgery (laparoscopic or thoracoscopic surgery) under general anaesthesia. Exclusion Criteria: * Known to be allergic to dexamethasone; * Any systemic glucocorticoids within 3 months before trial entry; * History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al); * Cognitive impairment or severe mental illness; * Uncontrolled diabetes or infectious diseases; * Pregnancy or breastfeeding.